Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population

Lagerstedt-Robinson,Kristina; Rohlin,Anna; Aravidis,Christos; Melin,Beatrice; Nordling,Margareta; Stenmark-Askmalm,Marie; Lindblom,Annika; Nilbert,Mef

doi:10.3892/or.2016.5060

Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population

Authors:
- Kristina Lagerstedt-Robinson
- Anna Rohlin
- Christos Aravidis
- Beatrice Melin
- Margareta Nordling
- Marie Stenmark-Askmalm
- Annika Lindblom
- Mef Nilbert
View Affiliations

Affiliations: Department of Molecular Medicine and Surgery, Karolinska Institute and Department of Clinical Genetics, Karolinska University Hospital, Solna, SE-17176 Stockholm, Sweden, Department of Clinical Pathology and Genetics, Sahlgrenska University Hospital, SE-41345 Gothenburg, Sweden, Department of Immunology, Genetics and Pathology, Uppsala University, SE-75185 Uppsala, Sweden, Department of Radiation Sciences, Division of Oncology, Umeå University, SE-90187 Umeå, Sweden, Department of Oncology, Linköping University, SE-58183 Linköping, Sweden, Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, SE-22381 Lund, Sweden
Published online on: September 1, 2016 https://doi.org/10.3892/or.2016.5060
Pages: 2823-2835

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lynch syndrome caused by constitutional mismatch‑repair defects is one of the most common hereditary cancer syndromes with a high risk for colorectal, endometrial, ovarian and urothelial cancer. Lynch syndrome is caused by mutations in the mismatch repair (MMR) genes i.e., MLH1, MSH2, MSH6 and PMS2. After 20 years of genetic counseling and genetic testing for Lynch syndrome, we have compiled the mutation spectrum in Sweden with the aim to provide a population-based perspective on the contribution from the different MMR genes, the various types of mutations and the influence from founder mutations. Mutation data were collected on a national basis from all laboratories involved in genetic testing. Mutation analyses were performed using mainly Sanger sequencing and multiplex ligation-dependent probe amplification. A total of 201 unique disease-predisposing MMR gene mutations were identified in 369 Lynch syndrome families. These mutations affected MLH1 in 40%, MSH2 in 36%, MSH6 in 18% and PMS2 in 6% of the families. A large variety of mutations were identified with splice site mutations being the most common mutation type in MLH1 and frameshift mutations predominating in MSH2 and MSH6. Large deletions of one or several exons accounted for 21% of the mutations in MLH1 and MSH2 and 22% in PMS2, but were rare (4%) in MSH6. In 66% of the Lynch syndrome families the variants identified were private and the effect from founder mutations was limited and predominantly related to a Finnish founder mutation that accounted for 15% of the families with mutations in MLH1. In conclusion, the Swedish Lynch syndrome mutation spectrum is diverse with private MMR gene mutations in two-thirds of the families, has a significant contribution from internationally recognized mutations and a limited effect from founder mutations.

View Figures

View References

1	Carethers JM and Stoffel EM: Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer. World J Gastroenterol. 21:9253–9261. 2015. View Article : Google Scholar : PubMed/NCBI
2	de la Chapelle A: The incidence of Lynch syndrome. Fam Cancer. 4:233–237. 2005. View Article : Google Scholar : PubMed/NCBI
3	Sijmons RH and Hofstra RM: Review: Clinical aspects of hereditary DNA Mismatch repair gene mutations. DNA Repair (Amst). 38:155–162. 2016. View Article : Google Scholar
4	Thompson BA, Spurdle AB, Plazzer JP, Greenblatt MS, Akagi K, Al-Mulla F, Bapat B, Bernstein I, Capellá G, den Dunnen JT, et al InSiGHT: Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet. 46:107–115. 2014. View Article : Google Scholar
5	Peltomäki P: Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol. 21:1174–1179. 2003. View Article : Google Scholar : PubMed/NCBI
6	Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, Igari T, Koike M, Chiba M and Mori T: Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet. 17:271–272. 1997. View Article : Google Scholar : PubMed/NCBI
7	Berends MJ, Wu Y, Sijmons RH, Mensink RG, van der Sluis T, Hordijk-Hos JM, de Vries EG, Hollema H, Karrenbeld A, Buys CH, et al: Molecular and clinical characteristics of MSH6 variants: An analysis of 25 index carriers of a germline variant. Am J Hum Genet. 70:26–37. 2002. View Article : Google Scholar
8	Nilbert M, Wikman FP, Hansen TV, Krarup HB, Orntoft TF, Nielsen FC, Sunde L, Gerdes AM, Cruger D, Timshel S, et al: Major contribution from recurrent alterations and MSH6 mutations in the Danish Lynch syndrome population. Fam Cancer. 8:75–83. 2009. View Article : Google Scholar
9	Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, Lindblom A, Lagerstedt K, Thibodeau SN, Lindor NM, et al: The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology. 135:419–428. 2008. View Article : Google Scholar : PubMed/NCBI
10	Niessen RC, Hofstra RM, Westers H, Ligtenberg MJ, Kooi K, Jager PO, de Groote ML, Dijkhuizen T, Olderode-Berends MJ, Hollema H, et al: Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer. 48:737–744. 2009. View Article : Google Scholar : PubMed/NCBI
11	Goel A, Nguyen TP, Leung HC, Nagasaka T, Rhees J, Hotchkiss E, Arnold M, Banerji P, Koi M, Kwok CT, et al: De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one. Int J Cancer. 128:869–878. 2011. View Article : Google Scholar
12	Kuiper RP, Vissers LE, Venkatachalam R, Bodmer D, Hoenselaar E, Goossens M, Haufe A, Kamping E, Niessen RC, Hogervorst FB, et al: Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat. 32:407–414. 2011. View Article : Google Scholar : PubMed/NCBI
13	Nyström-Lahti M, Kristo P, Nicolaides NC, Chang SY, Aaltonen LA, Moisio AL, Järvinen HJ, Mecklin JP, Kinzler KW, Vogelstein B, et al: Founding mutations and Alu-mediated recombination in hereditary colon cancer. Nat Med. 1:1203–1206. 1995. View Article : Google Scholar : PubMed/NCBI
14	Grindedal EM, Aarset H, Bjørnevoll I, Røyset E, Mæhle L, Stormorken A, Heramb C, Medvik H, Møller P and Sjursen W: The Norwegian PMS2 founder mutation c.989-1G > T shows high penetrance of microsatellite instable cancers with normal immunohistochemistry. Hered Cancer Clin Pract. 12:122014. View Article : Google Scholar
15	Foulkes WD, Thiffault I, Gruber SB, Horwitz M, Hamel N, Lee C, Shia J, Markowitz A, Figer A, Friedman E, et al: The founder mutation MSH2*1906G→C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet. 71:1395–1412. 2002. View Article : Google Scholar : PubMed/NCBI
16	Sun S, Greenwood CM, Thiffault I, Hamel N, Chong G and Foulkes WD: The HNPCC associated MSH2*1906G→C founder mutation probably originated between 1440 CE and 1715 CE in the Ashkenazi Jewish population. J Med Genet. 42:766–768. 2005. View Article : Google Scholar : PubMed/NCBI
17	Goldberg Y, Porat RM, Kedar I, Shochat C, Galinsky D, Hamburger T, Hubert A, Strul H, Kariiv R, Ben-Avi L, et al: An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC. Fam Cancer. 9:141–150. 2010. View Article : Google Scholar
18	Raskin L, Schwenter F, Freytsis M, Tischkowitz M, Wong N, Chong G, Narod SA, Levine DA, Bogomolniy F, Aronson M, et al: Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome. Clin Genet. 79:512–522. 2011. View Article : Google Scholar
19	Tiwari AK, Roy HK and Lynch HT: Lynch syndrome in the 21st century: Clinical perspectives. QJM. 109:151–158. 2015. View Article : Google Scholar : PubMed/NCBI
20	Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F, Sandkuijl L, Møller P, Genuardi M, Van Houwelingen H, et al: Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: Impact on counseling and surveillance. Gastroenterology. 127:17–25. 2004. View Article : Google Scholar : PubMed/NCBI
21	Plaschke J, Engel C, Krüger S, Holinski-Feder E, Pagenstecher C, Mangold E, Moeslein G, Schulmann K, Gebert J, von Knebel Doeberitz M, et al: Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: The German Hereditary Nonpolyposis Colorectal Cancer Consortium. J Clin Oncol. 22:4486–4494. 2004. View Article : Google Scholar : PubMed/NCBI
22	ten Broeke SW, Brohet RM, Tops CM, van der Klift HM, Velthuizen ME, Bernstein I, Capellá Munar G, Gomez Garcia E, Hoogerbrugge N, Letteboer TG, et al: Lynch syndrome caused by germline PMS2 mutations: Delineating the cancer risk. J Clin Oncol. 33:319–325. 2015. View Article : Google Scholar
23	Stoffel E, Mukherjee B, Raymond VM, Tayob N, Kastrinos F, Sparr J, Wang F, Bandipalliam P, Syngal S and Gruber SB: Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology. 137:1621–1627. 2009. View Article : Google Scholar : PubMed/NCBI
24	Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, Aaltonen LA, Hopper JL, Le Marchand L, Gallinger S, Newcomb PA, et al EPICOLON Consortium: Identification of Lynch syndrome among patients with colorectal cancer. JAMA. 308:1555–1565. 2012. View Article : Google Scholar : PubMed/NCBI
25	den Dunnen JT and Antonarakis SE: Mutation nomenclature. Curr Protoc Hum genet. 37:7.13.1–7.13.8. 2003. View Article : Google Scholar
26	Lagerstedt Robinson K, Liu T, Vandrovcova J, Halvarsson B, Clendenning M, Frebourg T, Papadopoulos N, Kinzler KW, Vogelstein B, Peltomäki P, et al: Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst. 99:291–299. 2007. View Article : Google Scholar : PubMed/NCBI
27	Cederquist K, Emanuelsson M, Göransson I, Holinski-Feder E, Müller-Koch Y, Golovleva I and Grönberg H: Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with double primary cancers of the colorectum and the endometrium: A population-based study in northern Sweden. Int J Cancer. 109:370–376. 2004. View Article : Google Scholar : PubMed/NCBI
28	Charbonnier F, Olschwang S, Wang Q, Boisson C, Martin C, Buisine MP, Puisieux A and Frebourg T: MSH2 in contrast to MLH1 and MSH6 is frequently inactivated by exonic and promoter rearrangements in hereditary nonpolyposis colorectal cancer. Cancer Res. 62:848–853. 2002.PubMed/NCBI
29	Smith MJ, Urquhart JE, Harkness EF, Miles EK, Bowers NL, Byers HJ, Bulman M, Gokhale C, Wallace AJ, Newman WG, et al: The contribution of whole gene deletions and large rearrangements to the mutation spectrum in inherited tumor predisposing syndromes. Hum Mutat. 37:250–256. 2016. View Article : Google Scholar
30	Clendenning M, Baze ME, Sun S, Walsh K, Liyanarachchi S, Fix D, Schunemann V, Comeras I, Deacon M, Lynch JF, et al: Origins and prevalence of the American founder mutation of MSH2. Cancer Res. 68:2145–2153. 2008. View Article : Google Scholar : PubMed/NCBI
31	Tomsic J, Liyanarachchi S, Hampel H, Morak M, Thomas BC, Raymond VM, Chittenden A, Schackert HK, Gruber SB, Syngal S, et al: An American founder mutation in MLH1. Int J Cancer. 130:2088–2095. 2012. View Article : Google Scholar :
32	Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I and Hyde C: A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. Health Technol Assess. 18:1–406. 2014. View Article : Google Scholar : PubMed/NCBI